Literature DB >> 10741741

Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases.

J A McKay1, J J Douglas, V G Ross, S Curran, F Y Ahmed, J F Loane, G I Murray, H L McLeod.   

Abstract

Analysis of tumor markers focuses on expression in primary tumors with the assumption that this is representative of metastatic tumor, against which treatment is targeted. Few studies have compared the expression of such markers in primary and secondary tumors. In this study, several key genes involved in cell cycle regulation were investigated in colorectal tumors and corresponding lymph node metastases. The cell cycle regulators p53, cyclin D1, p21, p27, retinoblastoma protein (Rb), and proliferating cell nuclear antigen (PCNA) were examined in a series of 42 paired samples of primary colorectal and secondary lymph node tumors by immunohistochemistry. Expression of p53, p27, and Rb was similar in virtually all paired samples (p53, 38 of 42; p27, 39 of 42; Rb, 40 of 42), indicating that the pattern of these proteins in colorectal tumors may be used to predict that in lymph node tumors. It also suggests a lack of direct involvement in the metastatic process. A lower concordance for p21 and cyclin D1 staining was observed between primary and secondary tumors (p21, 19 of 42; cyclin D1, 22 of 42). p21 expression was more often observed in primary colorectal cancers, whereas cyclin D1 expression was more frequently seen in lymph node metastases, in keeping with the contrasting roles of these proteins as a cell cycle inhibitor (p21) and activator (cyclin D1). The PCNA-labeling index was found to vary considerably in a number of cases, thus limiting the ability to predict expression of this protein in lymph node metastases from the primary tumor. In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741741

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice.

Authors:  Robert W Engelman; Rosalind J Jackson; Domenico Coppola; Walker Wharton; Alan B Cantor; W Jack Pledger
Journal:  Exp Mol Pathol       Date:  2007-01-04       Impact factor: 3.362

2.  Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique.

Authors:  Cord Langner; Reinhard von Wasielewski; Manfred Ratschek; Peter Rehak; Richard Zigeuner
Journal:  Virchows Arch       Date:  2004-10-28       Impact factor: 4.064

3.  Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression?

Authors:  J M Fernández-Cebrián; M Nevado Santos; P Vorwald Kuborn; M Pardo de Lama; J Martín-Cavanna; P Pacheco Martínez; B Fernández Escudero; M Ramos Fernández
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

4.  A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.

Authors:  M T A Strous; T K E Faes; A L H M Gubbels; R L A van der Linden; W E Mesker; K Bosscha; C M Bronkhorst; M L G Janssen-Heijnen; F J Vogelaar; A P de Bruïne
Journal:  Clin Transl Oncol       Date:  2022-01-22       Impact factor: 3.405

5.  Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression.

Authors:  Zhengyu Fang; Wantong Yao; Yi Xiong; Jiana Li; Li Liu; Lei Shi; Wei Zhang; Chao Zhang; Liping Nie; Jun Wan
Journal:  BMC Cancer       Date:  2011-05-24       Impact factor: 4.430

6.  The proteomics of colorectal cancer: identification of a protein signature associated with prognosis.

Authors:  Donna O'Dwyer; Lynda D Ralton; Aisling O'Shea; Graeme I Murray
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

7.  Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer.

Authors:  Gregory Kouraklis; Stamos Theocharis; Panayiotis Vamvakas; Costas Vagianos; Andromahi Glinavou; Costas Giaginis; Crysoula Sioka
Journal:  World J Surg Oncol       Date:  2006-01-20       Impact factor: 2.754

8.  c-erbB-2 is not a major factor in the development of colorectal cancer.

Authors:  J A McKay; J F Loane; V G Ross; M-M Ameyaw; G I Murray; J Cassidy; H L McLeod
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

9.  Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.

Authors:  M P Myklebust; Z Li; T H Tran; H Rui; E S Knudsen; H Elsaleh; Ø Fluge; B Vonen; H E Myrvold; S Leh; K M Tveit; R G Pestell; O Dahl
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

10.  Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study.

Authors:  Zheng Liu; Qiang Fu; Jiaju Lv; Facheng Wang; Kejia Ding
Journal:  J Exp Clin Cancer Res       Date:  2008-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.